Theriva Biologics (NYSEAMERICAN:TOVX) Trading 3.4% Higher – Still a Buy?

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) shares were up 3.4% on Tuesday . The company traded as high as $0.2450 and last traded at $0.2388. Approximately 1,538,827 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 4,710,868 shares. The stock had previously closed at $0.2309.

Theriva Biologics Trading Up 3.4%

The company has a fifty day simple moving average of $0.36 and a 200-day simple moving average of $0.42. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.15. The stock has a market cap of $2.29 million, a price-to-earnings ratio of -0.01 and a beta of 0.65.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.45) EPS for the quarter.

Hedge Funds Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Two Sigma Investments LP bought a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned 0.64% of Theriva Biologics as of its most recent SEC filing. Hedge funds and other institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.